Skip to content

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Randomized, Placebo-controlled, Double-blind, Cross-over Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01928901
Enrollment
56
Registered
2013-08-27
Start date
2013-08-31
Completion date
2014-02-28
Last updated
2014-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Current Smokers

Brief summary

Proof of concept: Superiority of Bronchipret or Sinupret to placebo in respect to mucociliary clearance

Interventions

DRUGadministration of Sinupret
DRUGadministration of Bronchipret
DRUGadministration of Sinupret Placebo
DRUGadministration of Bronchipret Placebo

Sponsors

Bionorica SE
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Volunteers who have given their signed declaration of consent and have signed the data protection declaration 2. Male or female volunteers 25 - 40 years 3. Current smokers (5-20 cigarettes per day since 5 years at least) 4. Ability to taste sweetness of saccharin 5. Perception of sweetness within 30 minutes after placement of saccharin behind nasal valve

Exclusion criteria

1. Ciliary dyskinesia 2. Cystic fibrosis 3. COPD/emphysema 4. Asthma 5. Chronic rhinosinusitis 6. Acute respiratory tract infection within the last 6 weeks prior to enrolment 7. Septal or sinus surgery 8. Symptomatic allergic rhinitis 9. Known allergic rhinitis 10. Treatment with not-permitted previous or concomitant therapy 11. History of snuff consumption for longer than 1 month or intranasal consumption of recreational drugs such as cocaine or heroin for longer than 1 month 12. Any disease or condition that might affect the safety of the subject during the trial, according to the investigator's judgement

Design outcomes

Primary

MeasureTime frameDescription
Time to perception of sweetnessafter 7 days of treatmentTime to perception of sweetness after 7 days of treatment with the investigational products - relative to the time to perception of sweetness at the begin-ning of treatment

Secondary

MeasureTime frameDescription
Perception of Sweetness of Saccharin4 - 7 weeksTo measure the time to perception of sweetness of Saccharin after 7 days of treatment with the investigational products calculated as difference to time to perception of sweetness at the beginning of treatment. The time of sweetness will be measured in minutes and seconds.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026